Joseph Tam

Jerusalem, JM 91120, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

Progressive endocannabinoid system dysregulation in autosomal dominant polycystic kidney disease.

Progressive endocannabinoid system dysregulation in autosomal dominant polycystic kidney disease.

Journal: Molecular medicine (Cambridge, Mass.)

Published: January 09, 2026

Endocannabinoid responses to relief of obstruction in acute injured kidney: a prospective observational study.

Endocannabinoid responses to relief of obstruction in acute injured kidney: a prospective observational study.

Journal: Therapeutic advances in urology

Published: September 15, 2025

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration.

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration.

Journal: British journal of pharmacology

Published: August 18, 2025

Targeting the endocannabinoid system to suppress mTORC1 hyperactivation in TSC-associated kidney disease.

Targeting the endocannabinoid system to suppress mTORC1 hyperactivation in TSC-associated kidney disease.

Journal: American journal of physiology. Renal physiology

Published: July 24, 2025

Glucosamine links hyperglycemia to mTORC1 activation and glucose toxicity in diabetes.

Glucosamine links hyperglycemia to mTORC1 activation and glucose toxicity in diabetes.

Journal: JCI insight

Published: July 03, 2025

Blockade of Interleukin-6 Trans-signaling in the Presence of Certain Gut Microbiota Induces Mature-onset Obesity in Mice.

Blockade of Interleukin-6 Trans-signaling in the Presence of Certain Gut Microbiota Induces Mature-onset Obesity in Mice.

Journal: Gastro hep advances

Published: June 05, 2025

Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold.

Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold.

Journal: Journal of medicinal chemistry

Published: April 21, 2025

Metabolic consequences of altered kidney glucose reabsorption under normoglycemic conditions.

Metabolic consequences of altered kidney glucose reabsorption under normoglycemic conditions.

Journal: Molecular metabolism

Published: April 16, 2025

Botulinum Neurotoxins: History, Mechanism, and Applications. A Narrative Review.

Botulinum Neurotoxins: History, Mechanism, and Applications. A Narrative Review.

Journal: Journal of neurochemistry

Published: March 17, 2025

Correction: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans.

Correction: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans.

Journal: Diabetologia

Published: February 15, 2025

Hepatic CB1 receptor signaling triggers Gi/oα-mediated lipolysis in lean mice but Gsα-mediated lipogenesis in obese mice.

Hepatic CB1 receptor signaling triggers Gi/oα-mediated lipolysis in lean mice but Gsα-mediated lipogenesis in obese mice.

Journal: Metabolism: clinical and experimental

Published: February 14, 2025

Markedly Low Prevalence of Fatty Liver Despite Obesity in Prader-Willi Syndrome: A Search for Protective Genetic Markers.

Markedly Low Prevalence of Fatty Liver Despite Obesity in Prader-Willi Syndrome: A Search for Protective Genetic Markers.

Journal: Journal of clinical and experimental hepatology

Published: January 30, 2025

Showing 1-12 of 94

Last Updated: 09/26/2026